Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 09, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 09, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Erlotinib Tablets, 25 mg, 100 mg, and 150 mg".